This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Bronchopulmonary Dysplasia Treatment Market

Rising cases of Respiratory Abnormalities in Infants to spur treatment for Bronchopulmonary Dysplasia

Bronchopulmonary Dysplasia Treatment Market by Drug Type, Therapy, End User & Region - Forecast 2022 - 2032

Bronchopulmonary Dysplasia Treatment Market Snapshot (2022-2032)

[308 Pages Report] The global bronchopulmonary dysplasia treatment market is expected to garner a market value of US$ 346 Million in 2022 and is expected to accumulate US$ 661.7 Million by registering a CAGR of 6.1% in the forecast period 2022-2032. Growth of the bronchopulmonary dysplasia treatment market can be attributed to the increasing cases of bronchopulmonary dysplasia along with the rise in premature births across the globe. The market for bronchopulmonary dysplasia treatment registered a CAGR of 5.9% in the historical period 2016-2021.

Data Points

Key Statistics

Estimated Base Year Value (2021)

US$ 344.98 Million

Expected Market Value (2022)

US$ 346 Million

Anticipated Forecast Value (2032)

US$ 661.7 Million

Projected Growth Rate (2022-2032)

6.1% CAGR

Bronchopulmonary dysplasia is a chronic respiratory disease, which most commonly occurs in premature infants and who received supplemental oxygen or mechanical ventilation. It is also called as respiratory distress syndrome. In addition, bronchopulmonary dysplasia can also occur in infants who experience abnormal lung development or had pre-birth antenatal infection.

Most infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during adolescence and adulthood. This condition can cause serious complications during infancy and might requires hospitalization and intensive medical care, during the first 2 years after birth.

The signs and symptoms of BPS include shallow, rapid breathing, chronic cough, shortness of breath, flaring of nostrils while breathing, and discoloration of skin owing to low blood oxygen levels. Many cases of BPD are associated with excess oxygen levels and mechanical ventilation.

The disease can cause from other conditions such as antenatal infection, maternal complications, preeclampsia, and inflammation of the fetal membranes, that affects the development of the lungs.

Customize this Report

Let us know your requirement to get
100% FREE customization

2016-2021 Bronchopulmonary Dysplasia Treatment Demand Analysis vs. Forecast 2022-2032

The global demand for bronchopulmonary dysplasia treatment is projected to increase at a CAGR of 6.1% during the forecast period between 2022 and 2032, reaching a total of US$ 661.7 Million in 2032, according to a report from Future Market Insights (FMI). From 2016 to 2021, sales witnessed significant growth, registering a CAGR of 5.9%.

The prevalence of COVID-19 pandemic brought in the fear of bronchopulmonary dysplasia among healthcare professionals and parents. Thus, the demand for the treatment of the same increased drastically. Moreover, most healthcare facilities are preparing special units for the treatment of bronchopulmonary dysplasia.

Furthermore, most end user industries such as nursing homes and hospitals are ready with equipment that help in diagnosing and treating bronchopulmonary dysplasia. This, in turn, is favouring the growth of the market in the assessment period 2022-2032.

Which are Some Prominent Drivers of Bronchopulmonary Dysplasia Treatment Market?

Premature births creating opportunities for bronchopulmonary dysplasia treatment

According to the Airway estimates, in Europe and the U.S. up to 160,000 infants are at highest risk for the development of BPD collectively, each year. Government initiatives, favorable reimbursement policies, increasing prevalence of bronchopulmonary dysplasia, and raise in cases of premature births leading to bronchopulmonary dysplasia are boosting the growth of bronchopulmonary dysplasia treatment market over the forecast period.

Growing research and development activities by pharmaceutical companies to develop innovative treatment option for bronchopulmonary dysplasia would boost the market in near future.

Research and treatment options contributing to market growth

Companies are focusing on the development of novel treatment option for bronchopulmonary dysplasia for the faster action and quick relief than the conventional dosage forms. For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function in infants with bronchopulmonary dysplasia.

On the other hand, research is developing stem cell therapy for novel therapeutic modality for attenuating BPD severity. Moreover, the first phase I clinical trial of stem cell transplantation for bronchopulmonary dysplasia is successfully conducted by proving its safety and feasibility in the preterm infants.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Faced by the Bronchopulmonary Dysplasia Treatment Market?

Lack of awareness along with undiagnosed infants derailing growth

Long-term side effects of drugs in certain cases are becoming a matter of concern for certain infants. This, in turn, is creating obstacles for market growth. Moreover, high cost of treatment owing to the complex nature of the disease is another factor is impeding the market growth.

Furthermore, lack of awareness in developing countries leaves many infants undiagnosed. This, in turn, is increasing the death rate of infants. All these factors are derailing the progress of bronchopulmonary dysplasia treatment market.

Technological Advancements Creating Lucrative Opportunities for Bronchopulmonary Dysplasia Treatment Market in North America?

High treatment rate enhcaing growth of market

North America is expected to dominate the global market for bronchopulmonary dysplasia treatment due to favorable government policies, increased in awareness about the bronchopulmonary dysplasia, and high treatment rate are expected to drive the growth of the market over the forecast period.

Advancements in the healthcare sector along with continuous research and development in for treating bronchopulmonary dysplasia is favoring the market growth especially in the U.S. Thus, due to the reasons mentioned above, North America is expected to hold 41.2% market share for bronchopulmonary dysplasia treatment market in 2022.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Increasing Deaths of Infants Bolstering Early Diagnosis of Bronchopulmonary Dysplasia Treatment Market in Europe?

Undiagnosed cases alarming healthcare professionals to take action

Europe is witnessing a growth in the number of infants suffering from bronchopulmonary dysplasia. This is owing to the disease becoming more common in the region. In addition, most cases of bronchopulmonary dysplasia are undiagnosed, increasing the deaths of infants at an alarming rate. This has led to healthcare facilities in the region specifically paying attention to the cause of the diseases.

The strong presence of healthcare sectors in Netherlands along with government policies working in the favor of childcare are accelerating the growth of the bronchopulmonary dysplasia treatment market Thus, owing to the aforementioned reasons, Europe is expected to possess 37.2% market share for bronchopulmonary dysplasia treatment market in 2022.

Increasing Awareness and Favorable Policies Accelerating Growth of Bronchopulmonary Dysplasia Treatment Market in Asia Pacific?

Growth of preterm rate and government initiatives boosting dependency on treatment

With 73.6 million live births in Asia Pacific and a preterm rate <32 weeks of approximately 2.2%, the demand for bronchopulmonary dysplasia treatment has grown overtime. Rise in awareness toward treatment of the disease, and increase in health care expenditure are expected to boost the growth of the bronchopulmonary dysplasia treatment market growth.

Large patient pool along with government programs and initiatives are the key factors influencing the growth of the bronchopulmonary dysplasia treatment market in Asia Pacific. Thus, Asia Pacific is expected to procure 35% market share for bronchopulmonary dysplasia treatment market in 2022.

Category-Wise Insights

Effectiveness of Supplemental Oxygen Therapy a Dependable Treatment Option for Bronchopulmonary Dysplasia Treatment?

Safety of infants increasing reliability on supplemental oxygen therapy

The oxygen therapy segment is expected to hold a significant share of the global market during the forecast period due to factors such as effectiveness of drugs and more commonly used therapy.

In addition, oxygen supplement is an effective therapy with no risks involved and is safe for infants, making it a favorable option for treatment. Thus, supplemental oxygen supplement therapy is expected to hold 35% market share for bronchopulmonary dysplasia treatment market in 2022.

Availability of Different Treatments Making Hospitals a Feasible Option for Bronchopulmonary Dysplasia Treatment Market?

Immediate diagnosis and treatments making hospitals reliable

Based on end-user, the global bronchopulmonary dysplasia treatment market can be classified into hospitals, nursing homes, critical care units, and others. Amongst these, hospitals are expected to hold a significant share owing to the facilities and equipment they possess.

Moreover, most hospitals offer a variety of treatments for bronchopulmonary dysplasia making it feasible for immediate diagnosis and treatments. Thus, hospitals are expected to possess 40% market share for bronchopulmonary dysplasia treatment market in 2022.

Start-Ups in the Bronchopulmonary Dysplasia Treatment Market

Key start- up players in the bronchopulmonary dysplasia treatment market are AyuVis, Exvastat, Altavant Sciences, Atriva Therapeutics, ReAlta Life Sciences, and Omnispirant.

  • In May 2022, AyuVis secured $1.8 Million through Small Business Innovation Research Grant to support the research of its investigational product (AVR-48) targeting bronchopulmonary dysplasia treatment market.
  • Altavant, a key start-up in the bronchopulmonary dysplasia treatment market is focusing on creating small molecule inhibitors for respiratory disorders.

Market Competition

Some of the players in global bronchopulmonary dysplasia treatment market include Airway Therapeutics LLC, Chiesi Farmaceutici SpA, Insmed Incorporated, MediPost Co., Ltd., Meridigen Biotech Co., Ltd, Syntrix Biosystems, Inc., Therabron Therapeutics and others.

  • In March 2022, Airway Therapeutics LLC announced dosing of the first patient in the Phase 1b randomized trial AT-100 (rhSP-D) for preventative use in very preterm infants at risk for bronchopulmonary dysplasia (BPD). The clinical trial of the drug is expected to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.
  • Chiesi Farmaceutici SpA, a key player in the bronchopulmonary dysplasia treatment market is focusing on research for newer treatments and effective drugs that will increase recovery rate and reduce pain.

Report Scope

Report Attribute

Details

Market Value in 2022

US$ 346 Million

Market Value in 2032

US$ 661.7 Million

Growth Rate

CAGR of 6.1% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Million and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Drug Type
  • Therapy Type
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • Airway Therapeutics LLC
  • Chiesi Farmaceutici SpA
  • Insmed Incorporated
  • MediPost Co., Ltd.
  • Meridigen Biotech Co. Ltd
  • Syntrix Biosystems, Inc.
  • Martindale Pharmaceuticals
  • Takeda
  • Mallinckrodt
  • AdventHealth

Customization

Available Upon Request

Key Segments Profiled in the Bronchopulmonary Dysplasia Treatment Market Industry Survey

Bronchopulmonary Dysplasia Treatment Market by Drug Type:

  • Bronchopulmonary Dysplasia Treatment by Bronchodilators
  • Bronchopulmonary Dysplasia Treatment by Diuretics
  • Bronchopulmonary Dysplasia Treatment by Antibiotics
  • Bronchopulmonary Dysplasia Treatment by Steroids
  • Bronchopulmonary Dysplasia Treatment by Immunomodulators
  • Bronchopulmonary Dysplasia Treatment by Surfactant Homeostasis

Bronchopulmonary Dysplasia Treatment Market by Therapy Type:

  • Bronchopulmonary Dysplasia Treatment by Nitric Oxide Therapy
  • Bronchopulmonary Dysplasia Treatment by Protein replacement therapy
  • Bronchopulmonary Dysplasia Treatment by Stem Cell Therapy
  • Bronchopulmonary Dysplasia Treatment by Supplemental Oxygen

Bronchopulmonary Dysplasia Treatment Market by End User:

  • Bronchopulmonary Dysplasia Treatment by Hospitals
  • Bronchopulmonary Dysplasia Treatment by Nursing Homes
  • Bronchopulmonary Dysplasia Treatment by Critical Care Centers

Bronchopulmonary Dysplasia Treatment Market by Region:

  • North America Bronchopulmonary Dysplasia Treatment Market
  • Latin America Bronchopulmonary Dysplasia Treatment Market
  • Europe Bronchopulmonary Dysplasia Treatment Market
  • Asia Pacific Bronchopulmonary Dysplasia Treatment Market
  • Middle East & Africa Bronchopulmonary Dysplasia Treatment Market

Frequently Asked Questions

FMI projects the global bronchopulmonary dysplasia treatment market to expand at a 6.1% value CAGR by 2032

The global bronchopulmonary dysplasia treatment market is estimated at a market value of US$ 346 Million

The global bronchopulmonary dysplasia treatment market is expected to garner a market value of US$ 661.7 Million

North America is expected to hold 41.2% market share for bronchopulmonary dysplasia treatment market in 2022.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2016-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2022-2032

        5.3.1. Bronchodilators

        5.3.2. Diuretics

        5.3.3. Antibiotics

        5.3.4. Steroids

        5.3.5. Immunomodulators

        5.3.6. Surfactant Homeostasis

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2016-2021

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2022-2032

6. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Therapy Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Therapy Type, 2016-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy Type, 2022-2032

        6.3.1. Nitric Oxide Therapy

        6.3.2. Protein Replacement Therapy

        6.3.3. Stem Cell Therapy

        6.3.4. Supplemental Oxygen

    6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2016-2021

    6.5. Absolute $ Opportunity Analysis By Therapy Type, 2022-2032

7. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2016-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032

        7.3.1. Hospitals

        7.3.2. Nursing Homes

        7.3.3. Critical Care Centers

    7.4. Y-o-Y Growth Trend Analysis By End User, 2016-2021

    7.5. Absolute $ Opportunity Analysis By End User, 2022-2032

8. Global Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. US

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Therapy Type

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Therapy Type

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Therapy Type

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Therapy Type

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Type

        11.2.3. By Therapy Type

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Therapy Type

        11.3.4. By End User

    11.4. Key Takeaways

12. Asia Pacific Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Rest of Asia Pacific

        12.2.2. By Drug Type

        12.2.3. By Therapy Type

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Therapy Type

        12.3.4. By End User

    12.4. Key Takeaways

13. MEA Bronchopulmonary Dysplasia Treatment Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Drug Type

        13.2.3. By Therapy Type

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Therapy Type

        13.3.4. By End User

    13.4. Key Takeaways

14. Key Countries Bronchopulmonary Dysplasia Treatment Market Analysis

    14.1. US

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2021

            14.1.2.1. By Drug Type

            14.1.2.2. By Therapy Type

            14.1.2.3. By End User

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2021

            14.2.2.1. By Drug Type

            14.2.2.2. By Therapy Type

            14.2.2.3. By End User

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2021

            14.3.2.1. By Drug Type

            14.3.2.2. By Therapy Type

            14.3.2.3. By End User

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2021

            14.4.2.1. By Drug Type

            14.4.2.2. By Therapy Type

            14.4.2.3. By End User

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2021

            14.5.2.1. By Drug Type

            14.5.2.2. By Therapy Type

            14.5.2.3. By End User

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2021

            14.6.2.1. By Drug Type

            14.6.2.2. By Therapy Type

            14.6.2.3. By End User

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2021

            14.7.2.1. By Drug Type

            14.7.2.2. By Therapy Type

            14.7.2.3. By End User

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2021

            14.8.2.1. By Drug Type

            14.8.2.2. By Therapy Type

            14.8.2.3. By End User

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2021

            14.9.2.1. By Drug Type

            14.9.2.2. By Therapy Type

            14.9.2.3. By End User

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2021

            14.10.2.1. By Drug Type

            14.10.2.2. By Therapy Type

            14.10.2.3. By End User

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2021

            14.11.2.1. By Drug Type

            14.11.2.2. By Therapy Type

            14.11.2.3. By End User

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2021

            14.12.2.1. By Drug Type

            14.12.2.2. By Therapy Type

            14.12.2.3. By End User

    14.13. GCC Countries

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2021

            14.13.2.1. By Drug Type

            14.13.2.2. By Therapy Type

            14.13.2.3. By End User

    14.14. South Africa

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2021

            14.14.2.1. By Drug Type

            14.14.2.2. By Therapy Type

            14.14.2.3. By End User

    14.15. Israel

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2021

            14.15.2.1. By Drug Type

            14.15.2.2. By Therapy Type

            14.15.2.3. By End User

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug Type

        15.3.3. By Therapy Type

        15.3.4. By End User

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Airway Therapeutics LLC

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Chiesi Farmaceutici

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Insmed Incorporated

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. MediPost

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Meridigen Biotech

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Syntrix Biosystems

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Martindale Pharmaceuticals

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Takeda

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Oak Hill Bio

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Mallinckrodt

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

        16.1.11. AdventHealth

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Region, 2016-2032

Table 2: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032

Table 3: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032

Table 4: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 5: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 6: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032

Table 7: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032

Table 8: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 9: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 10: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032

Table 11: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032

Table 12: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 13: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 14: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032

Table 15: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032

Table 16: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 17: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 18: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032

Table 19: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032

Table 20: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 21: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 22: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Drug Type, 2016-2032

Table 23: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by Therapy Type, 2016-2032

Table 24: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Forecast by End User, 2016-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 2: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032

Figure 3: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032

Figure 4: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Region, 2022-2032

Figure 5: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Region, 2016-2032

Figure 6: Global Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032

Figure 9: Global Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 10: Global Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 11: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032

Figure 12: Global Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032

Figure 13: Global Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032

Figure 14: Global Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 15: Global Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 16: Global Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 17: Global Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032

Figure 18: Global Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032

Figure 19: Global Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032

Figure 20: Global Bronchopulmonary Dysplasia Treatment Market Attractiveness by Region, 2022-2032

Figure 21: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 22: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032

Figure 23: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032

Figure 24: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 25: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 26: North America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 27: North America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032

Figure 29: North America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 30: North America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 31: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032

Figure 32: North America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032

Figure 33: North America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032

Figure 34: North America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 35: North America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 36: North America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 37: North America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032

Figure 38: North America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032

Figure 39: North America Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032

Figure 40: North America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 42: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032

Figure 43: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032

Figure 44: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 45: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 46: Latin America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 47: Latin America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032

Figure 49: Latin America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 50: Latin America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 51: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032

Figure 52: Latin America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032

Figure 53: Latin America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032

Figure 54: Latin America Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 55: Latin America Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 56: Latin America Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 57: Latin America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032

Figure 58: Latin America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032

Figure 59: Latin America Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032

Figure 60: Latin America Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032

Figure 61: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 62: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032

Figure 63: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032

Figure 64: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 65: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 66: Europe Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 67: Europe Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032

Figure 69: Europe Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 70: Europe Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 71: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032

Figure 72: Europe Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032

Figure 73: Europe Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032

Figure 74: Europe Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 75: Europe Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 76: Europe Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 77: Europe Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032

Figure 78: Europe Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032

Figure 79: Europe Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032

Figure 80: Europe Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032

Figure 81: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 82: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032

Figure 83: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032

Figure 84: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 85: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 86: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 87: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032

Figure 89: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 90: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 91: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032

Figure 92: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032

Figure 93: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032

Figure 94: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 95: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 96: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 97: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032

Figure 98: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032

Figure 99: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032

Figure 100: Asia Pacific Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032

Figure 101: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Drug Type, 2022-2032

Figure 102: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Therapy Type, 2022-2032

Figure 103: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by End User, 2022-2032

Figure 104: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 105: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 106: MEA Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 107: MEA Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Drug Type, 2016-2032

Figure 109: MEA Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Drug Type, 2022-2032

Figure 110: MEA Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Drug Type, 2022-2032

Figure 111: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by Therapy Type, 2016-2032

Figure 112: MEA Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by Therapy Type, 2022-2032

Figure 113: MEA Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by Therapy Type, 2022-2032

Figure 114: MEA Bronchopulmonary Dysplasia Treatment Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 115: MEA Bronchopulmonary Dysplasia Treatment Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 116: MEA Bronchopulmonary Dysplasia Treatment Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 117: MEA Bronchopulmonary Dysplasia Treatment Market Attractiveness by Drug Type, 2022-2032

Figure 118: MEA Bronchopulmonary Dysplasia Treatment Market Attractiveness by Therapy Type, 2022-2032

Figure 119: MEA Bronchopulmonary Dysplasia Treatment Market Attractiveness by End User, 2022-2032

Figure 120: MEA Bronchopulmonary Dysplasia Treatment Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Disposable Bronchoscopes Market

Published : May 2022

Healthcare

Bronchiectasis Therapeutic Market

Published : July 2020

Healthcare

Bronchoscopes Market

Published : December 2021

Healthcare

Bronchitis Treatment Market

Published : March 2016

Google translate

Bronchopulmonary Dysplasia Treatment Market